$20.97
-5.9%Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Chief Business Officer
Chief Executive Officer & Director
Compensation
$869,154
Chief Financial Officer & Chief Operating Officer
Compensation
$607,200
Chief Medical Officer and Head of Research & Development
Compensation
$736,700
Head of Technical Operations
Senior Vice President of People & Culture
Senior Vice President of Regulatory Affairs & Quality
Senior Vice President, General Counsel & Secretary
Compensation
$59,792
Vice President & Head of Biometrics
Vice President & Head of Clinical Development
During the last 12 months, insiders have purchased $1.19M worth of UPB shares, with no selling activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
102.6K
1.19M
0
0.00
+1.2M
+$1.19M
Renaud Ronald C Jr
Director
$198K
Chimovits Erez
Director
$198K
Ruddy Marcella K.
Director
$198K
Beckman Daniella
Director
$198K
Fleming Harold Edward
Director
$198K
No selling activity
Strong bullish signal with $1.19M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
UPB - Filing history and reports
No SEC filings available for UPB
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.